Showing results (201-210 of 523) with videos related to
Sort By:
Pageof 53
Acta Diabetologica|April 8, 2017
Determinants of glomerular filtration rate following bariatric surgery in individuals with severe, otherwise uncomplicated, obesity: an observational, prospective studyMarta Seghieri, Edoardo Vitolo, Livia Giannini, et al.Diabetes/Metabolism Research and Reviews|January 22, 2026
Effect of SGLT2 Inhibitors + DPP-4 Inhibitors on Urine Microbiota in Type 2 DiabetesMarco Calvigioni, Edoardo Biancalana, Chiara Rossi, et al.Journal of the American College of Cardiology|September 3, 2002
Evaluation of the extent and duration of the "ABPM effect" in hypertensive patientsRamón C Hermida, Carlos Calvo, Diana E Ayala, et al.Oxidative Medicine and Cellular Longevity|December 23, 2017
Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High-Fat Diet: Possible Role of the NLRP3 InflammasomeClaudia Blasetti Fantauzzi, Stefano Menini, Carla Iacobini, et al.The Journal of Clinical Endocrinology and Metabolism|November 22, 2018
Phthalates Exposure as Determinant of Albuminuria in Subjects With Type 2 Diabetes: A Cross-Sectional StudyAlessandro Mengozzi, Fabrizia Carli, Edoardo Biancalana, et al.Cardiovascular Diabetology|October 25, 2017
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot studyAnna Solini, Livia Giannini, Marta Seghieri, et al.Nucleosides, Nucleotides & Nucleic Acids|December 2, 2004
The pathophysiology of hyperuricemia in essential hypertension: a pilot studyJuan G Puig, Rosa J Torres, Luis M Ruilope, et al.Journal of the American Society of Nephrology : JASN|February 20, 2010
Avosentan for overt diabetic nephropathyJohannes F E Mann, Damian Green, Kenneth Jamerson, et al.Blood Pressure|November 18, 2008
The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvementsLars Rydén, Bernard Waeber, Luis M Ruilope, et al.Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic ApproachPaola Orlandi, Anna Solini, Marta Banchi, et al.Pageof 53